{"prompt": "['2014-0546', 'August 7, 2017', 'Page 2 of 49', 'TABLE OF CONTENTS', 'TABLE OF CONTENTS', '2', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', '4', '1. INTRODUCTION', '8', '1.1. Description of the Investigational Product', '8', '1.2. Summary of Clinical Findings Relevant to the Trial', '8', '1.3. Summary of Potential Risks', '12', '1.4.', 'Study Rationale', '17', '2.', 'STUDY OBJECTIVES', '17', '3.', 'INVESTIGATIONAL PLAN', '17', '3.1.', 'Study Design', '17', '3.2. Selection of Study Population', '19', '3.2.1. Inclusion Criteria', '19', '3.2.2. Exclusion Criteria', '20', '3.3.', 'Removal of Patients from the Study', '21', '3.4.', 'Study Procedures', '21', '3.4.1. Efficacy Assessments', '22', '3.4.1.1.', 'Efficacy Outcomes', '22', '3.4.1.2.', 'Bone Marrow Examination and Cytogenetics', '22', '3.4.1.3.', 'Exploratory Genomics/Molecular Evaluation in Peripheral Blood', 'Samples', '23', '3.4.2. Safety Assessments', '23', '3.5. Treatments', '24', '3.5.1. Method of Assigning Patients to Treatment Groups', '24', '3.5.2. Treatments Administered', '24', '3.5.3. Management of Clinical Supplies', '25', '3.5.4. Rigosertib Dosing Adjustments', '26', '3.5.4.1.', 'Hematologic Toxicity', '26', '3.5.4.2.', 'Non-hematologic Toxicity - Hyponatremia', '26', '3.5.4.2.1. Treatment-related Urinary Symptoms', '26', '3.5.4.2.2. Treatment-related >Grade 2 Toxicity other than Urinary', 'Symptoms', '27', '3.5.5. Treatment Compliance', '27', '3.5.6. Management of Urinary Symptoms', '28', '3.5.7. Concomitant Therapy', '28']['2014-0546', 'August 7, 2017', 'Page 3 of 49', '3.6. Statistical Methods', '28', '3.6.1.', 'Sample Size Considerations', '28', '3.6.2.', 'Analysis Populations', '29', '3.6.3. Final Analyses', '29', '3.6.3.1.', 'Efficacy Analyses', '29', '3.6.3.2.', 'Safety Analyses', '30', '3.6.3.3.', 'Additional Analyses', '30', \"4. INVESTIGATOR'S OBLIGATIONS\", '31', '4.1.', 'Reporting Adverse Events', '31', '4.1.1. Serious Adverse Event Reporting', '31', '4.1.2', 'Reporting Forms', '29', '4.2', 'Investigator Communications with Onconova', '29', '4.3', 'Pregnancies', '29', '5.', 'REFERENCE LIST', '33', '6.', 'APPENDICES', '35', 'Appendix 1: WHO Criteria for Diagnosis of Primary Myelofibrosis, Essential', 'Thrombocythemia, and Polycythemia Vera', '36', 'Appendix 2: 2008 IWG-MRT Diagnosis Criteria for Post-Polycythemia Vera and Post-', 'Essential Thrombocythemia Myelofibrosis', '38', 'Appendix 3: Eastern Cooperative Oncology Group (ECOG) Performance Status', '40', 'Appendix 4: 2013 IWG-MRT Revised Response Criteria for Myelofibrosis', '41', 'Appendix 5: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom', 'Score (MPN-SAF TSS)', '44', 'Appendix 6: Schedule of Events and Procedures', '44', 'Appendix 7: List of Clinical Laboratory Tests', '47', 'Appendix 8: List of Potential Substrates of CYP 2C8 and 2C9', '48', 'Appendix 9: List of Potential Inhibitors of P-gp', '49']\n\n###\n\n", "completion": "END"}